ZW27941, a potent VHL-based #PROTAC, degrades METTL3/METTL14 to suppress #AML by downregulating c-Myc/BCL2 and disrupting key pathways, while synergizing with #cytarabine & #venetoclax for therapy. @ufresearch.bsky.social @ufhealthcancer.bsky.social

Read: doi.org/10.1016/j.ge...

Synapse: Your Connection to our MSK Authors.
Meet: Kelsey E. Breen
Research Focus: Medicine; Lead Genetic Counselor

Paired tumor-normal sequencing provides insights into the CDKN2A-associated tumor spectrum
#AcuteMyeloidLeukemia #AML #Cytarabine

synapse.mskcc.org/synapse/work...

Intermediate Dose of Cytarabine as Effective as Higher Dose for Post-Induction in AML | ASH Clinical News | American Society of Hematology

New research supports the assertion that a post-induction intermediate dose of #cytarabine may be sufficient to prevent relapse with less toxicity compared with a high dose in newly diagnosed #AML, as both doses resulted in similar rates of five-year OS: ow.ly/rlaZ50XcIef
#HemeSky #OncSky #leukemia

The October issue is out now! Highlights include a feature on recent technological advancements in #hematopathology, results on quad induction therapy for #MMsm and intermediate dose #cytarabine post-induction in #AML, and more. See the full lineup here: ow.ly/rfTn50X81bG
#HemeSky #OncSky

Same same but different - Nature Reviews Cancer In a recent study published in Nature, Liu, Wang, et al. investigate the mechanisms underlying cytarabine-induced neurotoxicity and provide a mechanistic explanation for the differing neurotoxicity profiles of other nucleoside analogues, such as gemcitabine.

#ResearchHighlight 🚨
In a recent study, the Nussenzweig lab investigated the mechanisms underlying #cytarabine-induced neurotoxicity and provide a mechanistic explanation for the differing neurotoxicity profiles of #gemcitabine.
📖⬇️